Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer

• Main Authors: Chen XH, Li ZQ, Peng H, Jin SM, Fu HQ, Zhu TC, Weng XG
• Format: Article
• Language: English
• Published: Dove Medical Press 2013-05-01
• Series: OncoTargets and Therapy
• Online Access: http://www.dovepress.com/type-1-insulin-like-growth-factor-receptor-monoclonal-antibody-hx-1162-a13049

Xue-Hui Chen, Zhi-Qiang Li, Hua Peng, Su-Mei Jin, Hui-Qing Fu, Tie-Chui Zhu, Xiao-Gang WengThe First Affiliated Hospital of Xinxiang Medical University, Weihui, People's Republic of ChinaAbstract: One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-R1. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-R1 targeting therapy provides a new avenue toward treating liver cancer.Keywords: IGF, IGF-R1, apoptosis, hepatocellular carcinoma